MaxCyte (MXCT) announced they are entering into a strategic platform license with TG Therapeutics (TGTX). Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue. TG Therapeutics entered into an agreement with Precision BioSciences (DTIL) and acquired a worldwide license to Precision’s Azercabtagene Zapreleucel, an investigational allogeneic or “off the shelf” CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications. TG received clearance by the FDA of an investigational new drug application for azer-cel in progressive forms of multiple sclerosis and is targeting commencement of a Phase 1 trial in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXCT:
- MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy
- MaxCyte to Announce 2024 Financial Results and Engage in Key Investor Conference
- MaxCyte Expands Stock Capital with New Common Stock Issuance
- MaxCyte Announces Executive Stock Transaction
- MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion
Questions or Comments about the article? Write to editor@tipranks.com